Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 22

Results For "specialty"

583 News Found

Senores receives ANDA approval for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet USP
Drug Approval | January 13, 2025

Senores receives ANDA approval for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet USP

Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate, a beta adrenoceptor blocker and hydrochlorothiazide (HCTZ), a thiazide diuretic, indicated for the treatment of hypertension, to lower blood pressure


Apotex acquires US rights to PROVIGIL and NUVIGIL
News | January 13, 2025

Apotex acquires US rights to PROVIGIL and NUVIGIL

PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy


ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe
News | January 10, 2025

ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe

According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually


JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health
News | January 09, 2025

JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health

He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)


Yatharth Hospital acquires hospital in New Delhi
News | January 05, 2025

Yatharth Hospital acquires hospital in New Delhi

The acquired hospital is a well-established hospital based out of Model Town, New Delhi


Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
News | January 01, 2025

Anthem Biosciences files DRHP for Rs. 3,395 crore IPO

Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients


Senores Pharmaceuticals IPO lists at 53% premium
News | December 31, 2024

Senores Pharmaceuticals IPO lists at 53% premium

The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline


Syensqo and Emulseo collaborate to advance microfluidic technology in healthcare sector
News | December 24, 2024

Syensqo and Emulseo collaborate to advance microfluidic technology in healthcare sector

Exploring new opportunities within the fast-growing market of microfluidics


Metropolis Healthcare acquires Core Diagnostics for Rs. 246.8 Cr
Clinical Trials | December 09, 2024

Metropolis Healthcare acquires Core Diagnostics for Rs. 246.8 Cr

Aims to become India’s leading cancer testing company